PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
- Conditions
- Hypertension
- Registration Number
- NCT00274599
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Demonstrate that telmisartan 80mg was at least as effective and possibly superior to ramipril 5mg \& 10mg in lowering mean ambulatory DBP and SBP during the last 6 hrs of the 24-hr dosing interval in mild-to-moderate hypertensives at the end of 8 and 14 week treatment phases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 812
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in the last 6-hr mean DBP & SBP as measured by ABPM at the end of and 8-wk treatment period (T80 vs R5 mg) and 14-wk treatment period (T80 vs R10 mg) Up to week 14
- Secondary Outcome Measures
Name Time Method Change from baseline in last 6-hr ABPM mean for: pulse pressure; DBP, SBP and PP; DBP/SBP/PP in the morning, daytime and nighttime periods of the 24-hr dosing interval; Change from baseline in mean, seated, trough DBP & SBP measured by manual cuff Up to week 14
Trial Locations
- Locations (10)
Spartanburg Medical Research
🇺🇸Spartanburg, South Carolina, United States
Harold B. Betton, M.D.
🇺🇸Little Rock, Arkansas, United States
GFI Pharmaceuticals
🇺🇸Evansville, Indiana, United States
205-13085 Yonge St
🇨🇦Richmond Hill, Ontario, Canada
R/D Clinical Research, Inc.
🇺🇸Lake Jackson, Texas, United States
155 Ontario Street
🇨🇦St. Catharines, Ontario, Canada
Attn: Ginger Paselk
🇺🇸Long Beach, California, United States
725 6E Rue
🇨🇦Val D'Or, Quebec, Canada
Boehringer Ingelheim Investigational Site
🇨🇦Saskatoon, Saskatchewan, Canada
4 rue Robinson Nord
🇨🇦Granby, Quebec, Canada